Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The program, which began on August 7, 2024, is part of a larger 12-month initiative to buy back shares worth up to DKK 20 billion, starting from February 6, 2024. As of October 4, 2024, Novo Nordisk has repurchased 12,896,648 B shares at an average price of DKK 879.22 per share, totaling DKK 11,339,024,603. The transactions from September 30 to October 4, 2024, saw the acquisition of 225,464 B shares for DKK 177,760,424. Following these purchases, Novo Nordisk holds 14,225,279 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, founded in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.

Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The program, which began on August 7, 2024, is part of a larger 12-month initiative to buy back shares worth up to DKK 20 billion, starting from February 6, 2024. As of October 4, 2024, Novo Nordisk has repurchased 12,896,648 B shares at an average price of DKK 879.22 per share, totaling DKK 11,339,024,603. The transactions from September 30 to October 4, 2024, saw the acquisition of 225,464 B shares for DKK 177,760,424. Following these purchases, Novo Nordisk holds 14,225,279 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, founded in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.